PTGX Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. (PTGX) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is $2.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.8% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Sector
Healthcare
Industry
Biotechnology